Myeloma BCMA Therapy In Spotlight: EMA Considers Fast Tracking GSK Filing
EU Filing Understood To Be Expected in H1 2020
The European Medicines Agency is this week deciding whether GlaxoSmithKline’s planned EU marketing application for its BCMA-targeting therapy merits an accelerated assessment.
